What is Zacks Research’s Estimate for IQVIA Q1 Earnings?

IQVIA Holdings Inc. (NYSE:IQV) – Research analysts at Zacks Research lowered their Q1 2025 earnings per share (EPS) estimates for IQVIA in a note issued to investors on Thursday, November 21st. Zacks Research analyst R. Department now anticipates that the medical research company will post earnings of $2.34 per share for the quarter, down from their previous forecast of $2.49. The consensus estimate for IQVIA’s current full-year earnings is $10.17 per share. Zacks Research also issued estimates for IQVIA’s Q2 2025 earnings at $2.59 EPS and FY2025 earnings at $10.58 EPS.

A number of other analysts have also commented on IQV. Robert W. Baird reduced their price target on shares of IQVIA from $256.00 to $223.00 and set a “neutral” rating for the company in a research note on Friday, November 1st. StockNews.com raised shares of IQVIA from a “hold” rating to a “buy” rating in a research report on Wednesday, November 20th. The Goldman Sachs Group lowered their price target on IQVIA from $280.00 to $250.00 and set a “buy” rating on the stock in a report on Friday, November 1st. BTIG Research cut their price objective on IQVIA from $290.00 to $260.00 and set a “buy” rating for the company in a report on Friday, November 1st. Finally, Barclays lowered their target price on IQVIA from $260.00 to $255.00 and set an “overweight” rating on the stock in a report on Friday, November 1st. Four analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, IQVIA has an average rating of “Moderate Buy” and an average target price of $256.50.

IQVIA Price Performance

NYSE IQV opened at $204.02 on Monday. IQVIA has a one year low of $187.62 and a one year high of $261.73. The stock has a 50-day moving average of $221.96 and a 200 day moving average of $226.98. The company has a debt-to-equity ratio of 1.76, a quick ratio of 0.81 and a current ratio of 0.81. The company has a market capitalization of $37.03 billion, a price-to-earnings ratio of 26.77, a PEG ratio of 2.08 and a beta of 1.51.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Versant Capital Management Inc lifted its position in shares of IQVIA by 733.3% in the second quarter. Versant Capital Management Inc now owns 125 shares of the medical research company’s stock valued at $26,000 after acquiring an additional 110 shares in the last quarter. Opal Wealth Advisors LLC purchased a new position in IQVIA in the 2nd quarter worth approximately $27,000. Capital Performance Advisors LLP bought a new position in IQVIA in the 3rd quarter worth approximately $27,000. Park Place Capital Corp purchased a new stake in IQVIA during the 3rd quarter valued at approximately $28,000. Finally, Itau Unibanco Holding S.A. bought a new stake in shares of IQVIA during the second quarter valued at approximately $29,000. Institutional investors own 89.62% of the company’s stock.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.